Healthcare / Drug Manufacturers - GeneralBSE
$3170.35
+52.15 (+1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.1B · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.0B
P/E
23.6x
↑EV/EBITDA
14.6x
↑ROE
43.6%
↑Gross Margin
50.3%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.6%
FCF CAGR
+3.1%
FCF margin
22.6%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.23B · net income $3.27B · FCF $4.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.23B | $18.23B | $19.89B | $19.82B | $27.27B |
| Net Income | $3.27B | $3.27B | $4.13B | $6.03B | $6.21B |
| EBITDA | $4.84B | $4.84B | $4.71B | $5.70B | $9.08B |
| EPS | 141.85 | 141.85 | 179.54 | 261.78 | 269.47 |
| Gross Margin | 50.3% | 50.3% | 49.8% | 51.2% | 54.4% |
| Operating Margin | 24.9% | 24.9% | 22.8% | 22.9% | 24.4% |
| Net Margin | 17.9% | 17.9% | 20.8% | 30.4% | 22.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Cash Flow | |||||
| Free Cash Flow | $4.13B | $4.13B | $4.25B | $1.96B | $3.77B |
| Returns | |||||
| ROE | 43.6% | 43.6% | 48.0% | 59.4% | 48.6% |
| Valuation | |||||
| P/E | 23.59 | 23.59 | 34.14 | 32.16 | 21.25 |
| EV/EBITDA | 14.59 | 14.59 | 29.41 | 33.37 | 13.45 |
| P/B | 9.75 | 9.75 | 16.40 | 19.10 | 10.34 |
| Growth & Yield | |||||
| Revenue Growth | -8.3% | -8.3% | 0.4% | -27.3% | — |
| EPS Growth | -21.0% | -21.0% | -31.4% | -2.9% | — |
| Dividend Yield | 7.7% | 7.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.6%
EPS terminal req.
$281.32
Spread vs growth
-46.6%
5Y implied EPS CAGR
19.1%
EPS terminal req.
$340.39
Spread vs growth
-40.1%
10Y implied EPS CAGR
14.5%
EPS terminal req.
$548.20
Spread vs growth
-35.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.8%
Start / end P/E
35.0x → 22.4x
EPS bridge
179.54 → 141.85
Residual
+7.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.